Moleculin Biotech, Inc. (MBRX): Results of Operations and Financial Condition
Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial - Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML - MIRACLE trial ad
How this was made
The 30-second read
Why it matters
The key tradable elements are the quantified interim complete remission and composite CRc rates versus control, the stated enrollment progress toward a September 90-patient milestone, and the continued absence of cardiotoxicity, alongside cash runway guidance into 1Q 2027.
Market read
Traders can reassess probability-weighted clinical success and financing risk based on new interim efficacy percentages, enrollment status, and cash runway into 1Q 2027.
What to watch
Cash runway is into 1Q 2027, so any delay in Part B or additional trial costs could still force dilution before the next major unblinding window.
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
MIRACLE interim data and enrollment progress were positive, but the pre-revenue company reported a $7,635 (in thousands) net loss, had approximately $7.3 million of quarter-end cash, and stated it will require significant additional financing.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenues, three months ended June 30, 2026GAAP | $ - | – | – |
| Research and development, three months ended June 30, 2026GAAP | $5,450 (in thousands) | – | – |
| General and administrative, three months ended June 30, 2026GAAP | $2,103 (in thousands) | – | – |
| Depreciation and amortization, three months ended June 30, 2026GAAP | $8 (in thousands) | – | – |
| Total operating expenses, three months ended June 30, 2026GAAP | $7,561 (in thousands) | – | – |
| Loss from operations, three months ended June 30, 2026GAAP | $(7,561) (in thousands) | – | – |
| Gain (loss) from change in fair value of warrant liability, three months ended June 30, 2026GAAP | $(7) (in thousands) | – | – |
| Transaction costs allocated to warrant liabilities, three months ended June 30, 2026GAAP | $(2) (in thousands) | – | – |
| Loss on issuance of warrant liabilities, three months ended June 30, 2026GAAP | $- (in thousands) | – | – |
| Other income, net, three months ended June 30, 2026GAAP | $13 (in thousands) | – | – |
| Interest income, net, three months ended June 30, 2026GAAP | $(78) (in thousands) | – | – |
| Net loss, three months ended June 30, 2026GAAP | $(7,635) (in thousands) | – | – |
| Warrant deemed dividend, three months ended June 30, 2026GAAP | $(329) (in thousands) | – | – |
| Net loss available to common stockholders, three months ended June 30, 2026GAAP | $(7,964) (in thousands) | – | – |
| Net loss per common share - basic and diluted, three months ended June 30, 2026GAAP | $(1.40) | – | – |
| Weighted average common shares outstanding - basic and diluted, three months ended June 30, 2026GAAP | 5,680,717 | – | – |
| Revenues, six months ended June 30, 2026GAAP | $ - | – | – |
| Research and development, six months ended June 30, 2026GAAP | $10,828 (in thousands) | – | – |
| General and administrative, six months ended June 30, 2026GAAP | $4,591 (in thousands) | – | – |
| Depreciation and amortization, six months ended June 30, 2026GAAP | $16 (in thousands) | – | – |
| Total operating expenses, six months ended June 30, 2026GAAP | $15,435 (in thousands) | – | – |
| Loss from operations, six months ended June 30, 2026GAAP | $(15,435) (in thousands) | – | – |
| Gain (loss) from change in fair value of warrant liability, six months ended June 30, 2026GAAP | $10,763 (in thousands) | – | – |
| Transaction costs allocated to warrant liabilities, six months ended June 30, 2026GAAP | $(695) (in thousands) | – | – |
| Loss on issuance of warrant liabilities, six months ended June 30, 2026GAAP | $(15,158) (in thousands) | – | – |
| Other income, net, six months ended June 30, 2026GAAP | $88 (in thousands) | – | – |
| Interest income, net, six months ended June 30, 2026GAAP | $(43) (in thousands) | – | – |
| Net loss, six months ended June 30, 2026GAAP | $(20,480) (in thousands) | – | – |
| Warrant deemed dividend, six months ended June 30, 2026GAAP | $(2,094) (in thousands) | – | – |
| Net loss available to common stockholders, six months ended June 30, 2026GAAP | $(22,574) (in thousands) | – | – |
| Net loss per common share - basic and diluted, six months ended June 30, 2026GAAP | $(4.60) | – | – |
| Weighted average common shares outstanding - basic and diluted, six months ended June 30, 2026GAAP | 4,906,899 | – | – |
Clinical and liquidity outlook outlook
- NoteCash on hand and cash equivalents as of June 30, 2026, together with $9.3 million in financing proceeds raised subsequent to the quarter, expected to support planned operations into the first quarter of 2027.
- NoteSeptember 2026: Completion of enrollment in Part A of MIRACLE.
- NoteDecember 2026 to February 2027 timeframe: MIRACLE – data unblinding for Part A 90 subjects completed.
- Note2H 2026: Atlantic Health pancreatic cancer clinical trial begins.
- Note1H 2027: MIRACLE – Start of Part B.
- Note2027: Begin 3rd line R/R AML subject trial.
- Note2027: Begin pediatric AML clinical study.
- Note2028: End recruitment of Part B.
- Note2028: Primary efficacy data for MIRACLE 2nd line subjects.
- Note2028: Begin submission of a Rolling New Drug Application (NDA) for the treatment of R/R AML for accelerated approval on primary endpoint of CR from MIRACLE.
- Note2029: NDA submission complete.
What drove it
- Both Annamycin treatment arms demonstrated complete remission rates at least three times higher than the control arm in patients with relapsed or refractory AML.
- Complete remission reached 43% for 190 mg/m² plus cytarabine and 36% for 230 mg/m² plus cytarabine, compared with 12% for control.
- Composite complete remission reached 50% and 57%, respectively, versus 29% for the control arm.
- More than 80% of the planned 90 patients were enrolled as of the interim analysis.
- Research and development expense increased by $1.9 million, mainly related to the MIRACLE clinical trial of $1.1 million, additional nonclinical studies of $0.4 million, and $0.4 million in other research costs.
Concerns
- The Company reported no revenues for the three and six months ended June 30, 2026.
- The Company reported a $7,635 (in thousands) net loss for the three months ended June 30, 2026.
- Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in the press release.
- The milestones described in the release assume the Company’s ability to secure such financing on a timely basis.
- The MIRACLE results cited are preliminary unblinded efficacy results from the first 45 patients enrolled in Part A.
What to watch
- Completion of enrollment in Part A of MIRACLE in September 2026.
- MIRACLE data unblinding for Part A 90 subjects completed in the December 2026 to February 2027 timeframe.
- Selection of the optimal Annamycin dose and expected start of MIRACLE Part B in 1H 2027.
- Whether financing proceeds beyond the $9.3 million raised subsequent to the quarter are secured before the stated first quarter of 2027 cash runway.
- The 2H 2026 start of the Atlantic Health pancreatic cancer clinical trial.
Balance sheet and cash flow
- Cash and cash equivalents were $7,262 (in thousands) as of June 30, 2026, compared with $8,878 (in thousands) as of December 31, 2025.
- Prepaid expenses and other current assets were $1,461 (in thousands) as of June 30, 2026, compared with $808 (in thousands) as of December 31, 2025.
- Total current assets were $8,723 (in thousands) as of June 30, 2026, compared with $9,686 (in thousands) as of December 31, 2025.
- Intangible assets were $11,148 (in thousands) as of June 30, 2026 and $11,148 (in thousands) as of December 31, 2025.
- Other non-current assets were $900 (in thousands) as of June 30, 2026 and $900 (in thousands) as of December 31, 2025.
- Operating lease right-of-use asset was $254 (in thousands) as of June 30, 2026, compared with $314 (in thousands) as of December 31, 2025.
- Furniture and equipment, net was $62 (in thousands) as of June 30, 2026, compared with $78 (in thousands) as of December 31, 2025.
- Total assets were $21,087 (in thousands) as of June 30, 2026, compared with $22,126 (in thousands) as of December 31, 2025.
- Accounts payable and accrued expenses and other current liabilities were $9,313 (in thousands) as of June 30, 2026, compared with $6,854 (in thousands) as of December 31, 2025.
- Total current liabilities were $9,313 (in thousands) as of June 30, 2026, compared with $6,854 (in thousands) as of December 31, 2025.
- Operating lease liability - long-term, net of current portion was $147 (in thousands) as of June 30, 2026, compared with $222 (in thousands) as of December 31, 2025.
- Warrant liability - long term was $40 (in thousands) as of June 30, 2026, compared with $44 (in thousands) as of December 31, 2025.
- Total liabilities were $9,500 (in thousands) as of June 30, 2026, compared with $7,120 (in thousands) as of December 31, 2025.
- Total stockholders' equity was $11,587 (in thousands) as of June 30, 2026, compared with $15,006 (in thousands) as of December 31, 2025.
- Total liabilities and stockholders' equity were $21,087 (in thousands) as of June 30, 2026, compared with $22,126 (in thousands) as of December 31, 2025.
Analysis
Moleculin remains a pre-revenue clinical-stage company, reporting revenues of $ - and a GAAP net loss of $(7,635) (in thousands) for the three months ended June 30, 2026. The operating loss was $(7,561) (in thousands), with total operating expenses of $7,561 (in thousands). Research and development was $5,450 (in thousands), while general and administrative expense was $2,103 (in thousands). The stated increase in research and development was mainly associated with the MIRACLE clinical trial, additional nonclinical studies, and other research costs.
The principal operating development was the preliminary unblinded MIRACLE analysis from the first 45 Part A patients. Complete remission was 43% for the 190 mg/m² Annamycin plus cytarabine cohort and 36% for the 230 mg/m² cohort, compared with 12% for the cytarabine control arm. Composite complete remission was 50% and 57%, respectively, versus 29% for control. The company also stated that MIRACLE activity continues to demonstrate no evidence of cardiotoxicity, making the confirmation of both efficacy and cardiac safety at the planned data readout central to the program.
The near-term clinical timeline remains the primary catalyst set. More than 80% of the planned 90 patients were enrolled as of the interim analysis, with completion of Part A enrollment expected in September 2026 and the 90-subject data unblinding expected in the December 2026 to February 2027 timeframe. Management expects those data to support optimal dose selection and the start of Part B in 1H 2027. The release also identifies an Atlantic Health pancreatic cancer clinical trial expected to begin in 2H 2026.
Liquidity remains a material constraint. Cash and cash equivalents were $7,262 (in thousands) at June 30, 2026, and management cited $9.3 million of financing proceeds raised after quarter-end to support planned operations into the first quarter of 2027. The company explicitly stated that it will require significant additional financing, for which it has no commitments, to conduct the described clinical trials. There were no reported capital returns, operating cash flow, or free cash flow figures in the filing.
Compared with the prior-year quarter, the reported net loss was $(7,635) (in thousands) versus $(17,809) (in thousands), while research and development rose to $5,450 (in thousands) from $3,600 (in thousands). The year-to-date results include a $10,763 (in thousands) gain from change in fair value of warrant liability and a $(15,158) (in thousands) loss on issuance of warrant liabilities. Investors should focus on the forthcoming 90-subject MIRACLE readout, dose selection, the Part B start, and the company’s ability to finance its stated development plan.
Management, verbatim
In addition to the positive interim MIRACLE results, we are just as excited by the feedback we are receiving from investigators about Annamycin and their enthusiasm for participating in the study. Their response reflects both the significant unmet need in relapsed or refractory AML and growing recognition of Annamycin’s potential, with its encouraging data generated to date and differentiated cardiac safety profile, to play an important role in the treatment landscape. As we advance toward the 90-patient milestone and next unblinded efficacy readout, this strong investigator engagement adds to our confidence in the program and the potential for Annamycin to meaningfully improve outcomes for patients.
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
Not in the filing
stated, not guessed- Gross profit and gross margin
- Non-GAAP revenue, earnings, operating income, net income, or EPS measures
- Prior-quarter comparisons for reported income-statement metrics
- Percentage year-over-year and quarter-over-quarter changes for reported income-statement metrics
- Segment revenue disclosure
- Operating cash flow
- Free cash flow
- Capital expenditures
- Debt balance
- Share repurchases
- Dividend payments
- Revenue guidance
- Gross-margin guidance
- Operating-expense guidance
- Tax-rate guidance
- Previous-quarter outlook for comparison with actual results
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with an exhibit summarizing Q2 2026 financials and interim clinical progress for Annamycin in the pivotal adaptive Phase 2/3 MIRACLE trial in relapsed/refractory AML.
Ticker impact
Moleculin reported positive interim unblinded MIRACLE Phase 2/3 results, with complete remission rates 3x control and enrollment on track for a September 90-patient milestone.
Near-term upside bias on trial-readout momentum, with volatility around the next unblinded efficacy window (Dec 2026 to Feb 2027) and Part B start (1H 2027).
The filing is a primary disclosure (8-K with exhibit) containing specific efficacy percentages, enrollment progress, and cash runway into 1Q 2027, which can re-rate expectations for clinical success and financing needs.
Market effects
Reinforces investor appetite for anthracycline alternatives in AML that claim reduced cardiotoxicity, potentially lifting sentiment for similar oncology small caps.
Limited, primarily US small-cap biotech sentiment via Nasdaq-listed name.
Low direct global spillover; clinical-trial readouts can influence broader AML treatment narrative but not macro.
Counterpoint
Interim unblinded data from only 45 patients may not translate into durable survival or confirmatory endpoints, so the market may over-discount later efficacy and safety signals.
Key entities
- issuerMoleculin Biotech, Inc.
Nasdaq-listed company advancing Annamycin in the pivotal MIRACLE trial; reported interim unblinded efficacy and Q2 financial condition.
- investigational drugAnnamycin
Lead candidate evaluated with cytarabine in MIRACLE; interim data cited for CR and CRc rates and cardiac safety.
- clinical programMIRACLE trial
Adaptive Phase 2/3 study in relapsed/refractory AML with Part A unblinded efficacy and planned Part B initiation.
